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SUPPLEMENTARY MATERIAL: Figures, Information, and Tables 
Supplementary Figure S1. Kaplan-Meier plot of time to AF by Shanafelt risk score category (CLL 
patients with no prior history of AF randomized to ibrutinib). 
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Supplementary Figure 2. Swimmer’s plot of individual course of study treatment, concomitant 
medications, and clinical sequelae for patients with AF. 
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A, other arrhythmias; AE, adverse event; AF, atrial fibrillation; AFIB, atrial fibrillation/atrial flutter; C, 
congestive heart failure; CH, CHF and hypertension; CPT, completed study; DTH, death; H, hypertension; 
I, ischemic cardiac disease; PD, progressive disease; S, stroke; WC, withdrew consent.  
Anticoagulant/antiplatelet 
Ibrutinib 
Comparator 
AF onset 
Treatment discontinuation 
On treatment 
C  Advent of sequelae 
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Supplementary Figure 3. Incidence and highest toxicity grade bleeding events while on 
anticoagulation or antiplatelet medication in patients who had AF. 
AF, atrial fibrillation. 
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Supplementary Information 1 
Briefly, the RESONATE study enrolled 391 patients with previously treated CLL/SLL who were 
randomly assigned, in a 1:1 ratio, to receive either oral ibrutinib (420 mg once daily) until disease 
progression or occurrence of unacceptable toxic effects, or intravenous ofatumumab for up to 24 weeks 
at an initial dose of 300 mg at week 1, followed by a dose of 2000 mg weekly for 7 weeks and then every 
4 weeks for 16 weeks, consistent with local labeling. The randomization was stratified according to 
resistance to purine analog chemoimmunotherapy and chromosome 17p13.1 deletion.1 
The RESONATE-2 study enrolled 269 patients with treatment-naïve CLL/SLL without 17p deletion 
who were randomly assigned, in a 1:1 ratio, to either oral ibrutinib (420 mg once daily) or up to 12 cycles 
of chlorambucil (at a dose of 0.5 mg/kg of body weight on days 1 and 15 of each 28-day cycle, which was 
increased to a maximum of 0.8 mg/kg, if tolerable).2 
In the HELIOS study, 578 patients with previously treated CLL/SLL without 17p deletion were 
randomly assigned, in a double-blinded 1:1 ratio, to receive either ibrutinib (420 mg once daily) or 
placebo, in combination with BR. Ibrutinib or placebo were initiated in cycle 1 with BR and were 
continued until disease progression or unacceptable toxicity. BR was given for a maximum of 6 cycles (1 
cycle was 28 days; bendamustine: 70 mg/m² intravenously on days 2-3 in cycle 1, and days 1-2 in cycles 
2-6; rituximab: 375 mg/m² on day 1 of cycle 1, and 500 mg/m² on day 1 of cycles 2-6). 
The primary endpoint of all three CLL/SLL studies was the duration of PFS, as assessed by an 
independent review committee (IRC), according to the criteria of the International Workshop on Chronic 
Lymphocytic Leukemia (iwCLL).3 Key secondary end points included the duration of OS, response rate 
and safety.4 
The RAY study enrolled 280 patients with previously treated MCL who had received one or more prior 
rituximab-containing chemotherapy regimens. Patients were randomly assigned, in a 1:1 ratio, to 
 6 
 
ibrutinib (560 mg once daily) or intravenous temsirolimus (175 mg for a 3-week cycle followed by 75 
mg). The primary endpoint was PFS. Complete response, partial response, and progressive disease were 
assessed by an IRC per revised Cheson criteria.5 Secondary end points included overall response rate, 
OS, 1-year survival rate, duration of response, time to next treatment, safety, pre-specified patient-
reported outcomes, biomarkers, and pharmacokinetics.6 
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Supplementary Information 2 
CV events captured using MedDRA SMQ were grouped into five CVD categories: arrhythmia, 
congestive heart failure, ischemic heart disease, hypertension, and ischemic CNS vascular conditions 
Arrhythmia (modified MedDRA SMQ v16.0): Accelerated idioventricular rhythm, Accessory cardiac 
pathway, Acute coronary syndrome, Adams-Stokes syndrome, Agonal rhythm, Anomalous 
atrioventricular excitation, Arrhythmia, Arrhythmia supraventricular, Atrial conduction time 
prolongation, Atrial fibrillation, Atrial flutter, Atrial parasystole, Atrial tachycardia, Atrioventricular block, 
Atrioventricular block complete, Atrioventricular block first degree, Atrioventricular block second 
degree, Atrioventricular conduction time shortened, Atrioventricular dissociation, Bifascicular block, 
Bradyarrhythmia, Bradycardia, Brugada syndrome, Bundle branch block, Bundle branch block bilateral, 
Bundle branch block left, Bundle branch block right, Cardiac arrest, Cardiac death, Cardiac fibrillation, 
Cardiac flutter, Cardiac telemetry abnormal, Cardio-respiratory arrest, Chronotropic incompetence, 
Conduction disorder, ECG P wave inverted, Echocardiogram abnormal, Electrocardiogram abnormal, 
Electrocardiogram ambulatory abnormal, Electrocardiogram change, Electrocardiogram delta waves 
abnormal, Electrocardiogram P wave abnormal, Electrocardiogram PQ interval prolonged, 
Electrocardiogram PR prolongation, Electrocardiogram PR shortened, Electrocardiogram Q wave 
abnormal, Electrocardiogram QRS complex prolonged, Electrocardiogram QT interval abnormal, 
Electrocardiogram QT prolonged, Electrocardiogram repolarization abnormality, Electrocardiogram RR 
interval prolonged, Electrocardiogram U-wave abnormality, Extrasystoles, Heart alternation, Heart rate 
abnormal, Heart rate decreased, Heart rate increased, Heart rate irregular, Lenegre's disease, Long QT 
syndrome, Loss of consciousness, Nodal arrhythmia, Nodal rhythm, Pacemaker generated arrhythmia, 
Pacemaker syndrome, Palpitations, Parasystole, Paroxysmal arrhythmia, Pulseless electrical activity, 
Rebound tachycardia, Reduction ventriculoplasty, Reperfusion arrhythmia, Retrograde p-waves, Rhythm 
idioventricular, Sick sinus syndrome, Sinoatrial block, Sinus arrest, Sinus arrhythmia, Sinus bradycardia, 
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Sinus tachycardia, Sudden cardiac death, Sudden death, Supraventricular extrasystoles, Supraventricular 
tachyarrhythmia, Supraventricular tachycardia, Syncope, Tachyarrhythmia, Tachycardia, Tachycardia 
paroxysmal, Torsade de pointes, Trifascicular block, Ventricular arrhythmia, Ventricular asystole, 
Ventricular extrasystoles, Ventricular fibrillation, Ventricular flutter, Ventricular parasystole, Ventricular 
preexcitation, Ventricular tachyarrhythmia, Ventricular tachycardia, Wandering pacemaker, Withdrawal 
arrhythmia, Wolff-Parkinson-White syndrome. 
Congestive heart failure (modified MedDRA SMQ v16.0): Acute left ventricular failure, Acute 
pulmonary edema, Acute right ventricular failure, Artificial heart implant, Atrial natriuretic peptide 
abnormal, Atrial natriuretic peptide increased, Brain natriuretic peptide abnormal, Brain natriuretic 
peptide increased, Cardiac asthma, Cardiac cirrhosis, Cardiac failure, Cardiac failure acute, Cardiac 
failure chronic, Cardiac failure congestive, Cardiac failure high output, Cardiac index decreased, Cardiac 
output decreased, Cardiac resynchronization therapy, Cardiac ventriculogram abnormal, Cardiac 
ventriculogram left abnormal, Cardiac ventriculogram right abnormal, Cardiogenic shock, Cardiomegaly, 
Cardiopulmonary failure, Cardiorenal syndrome, Cardio-respiratory distress, Cardiothoracic ratio 
increased, Central venous pressure increased, Chronic left ventricular failure, Chronic right ventricular 
failure, Cor pulmonale, Cor pulmonale acute, Cor pulmonale chronic, Diastolic dysfunction, Dilatation 
ventricular, Dyspnea, Dyspnea paroxysmal nocturnal, Ejection fraction decreased, Heart transplant, 
Hepatic congestion, Hepatic vein dilatation, Hepatojugular reflux, Jugular vein distension, Left 
ventricular dysfunction, Left ventricular failure, Low cardiac output syndrome, Myocardial depression, 
Neonatal cardiac failure, Nocturnal dyspnea, N-terminal prohormone brain natriuretic peptide 
abnormal, N-terminal prohormone brain natriuretic peptide increased, Edema, Edema due to cardiac 
disease, Edema neonatal, Edema peripheral, Orthopnea, Peripheral edema neonatal, Pulmonary 
congestion, Pulmonary edema, Pulmonary edema neonatal, Right ventricular dysfunction, Right 
ventricular dysfunction, Right ventricular failure, Scan myocardial perfusion abnormal, Systolic 
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dysfunction, Venous pressure increased, Venous pressure jugular abnormal, Venous pressure jugular 
increased, Ventricular assist device insertion, Ventricular dysfunction, Ventricular dyssynchrony, 
Ventricular failure. 
Hypertension (modified MedDRA SMQ v16.0): Accelerated hypertension, Aldosterone urine abnormal, 
Aldosterone urine increased, Angiotensin converting enzyme increased, Angiotensin I increased, 
Angiotensin II increased, Blood aldosterone abnormal, Blood aldosterone increased, Blood 
catecholamines abnormal, Blood catecholamines increased, Blood pressure abnormal, Blood pressure 
ambulatory abnormal, Blood pressure ambulatory increased, Blood pressure diastolic abnormal, Blood 
pressure diastolic decreased, Blood pressure diastolic increased, Blood pressure fluctuation, Blood 
pressure fluctuation, Blood pressure inadequately controlled, Blood pressure inadequately controlled, 
Blood pressure increased, Blood pressure management, Blood pressure orthostatic abnormal, Blood 
pressure orthostatic increased, Blood pressure systolic abnormal, Blood pressure systolic decreased, 
Blood pressure systolic increased, Catecholamines urine abnormal, Catecholamines urine increased, 
Diastolic hypertension, Diuretic therapy, Eclampsia, Ectopic aldosterone secretion, Ectopic renin 
secretion, Endocrine hypertension, Epinephrine abnormal, Epinephrine increased, Essential 
hypertension, Gestational hypertension, HELLP syndrome, Hyperaldosteronism, Hypertension, 
Hypertension neonatal, Hypertensive angiopathy, Hypertensive cardiomegaly, Hypertensive 
cardiomyopathy, Hypertensive crisis, Hypertensive emergency, Hypertensive encephalopathy, 
Hypertensive heart disease, Hypertensive nephropathy, Hypertrophic cardiomyopathy, Labile blood 
pressure, Labile blood pressure, Labile hypertension, Malignant hypertension, Malignant hypertensive 
heart disease, Malignant renal hypertension, Maternal hypertension affecting fetus, Mean arterial 
pressure increased, Metabolic syndrome, Metanephrine urine abnormal, Metanephrine urine increased, 
Neurogenic hypertension, Non-dipping, Norepinephrine abnormal, Norepinephrine increased, 
Normetanephrine urine increased, Orthostatic hypertension, Pre-eclampsia, Prehypertension, 
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Procedural hypertension, Pseudoaldosteronism, Renal artery ablation, Renal hypertension, Renin 
abnormal, Renin increased, Renin-angiotensin system inhibition, Renovascular hypertension, 
Retinopathy hypertensive, Secondary aldosteronism, Secondary hypertension, Systolic hypertension, 
Tyramine reaction, Withdrawal hypertension. 
Ischemic heart disease (modified MedDRA SMQ v16.0): Acquired cardiac septal defect, Acute 
myocardial infarction, Angina pectoris, Angina unstable, Arteriogram coronary abnormal, 
Arteriosclerosis coronary artery, Arteriospasm coronary, Blood creatine phosphokinase abnormal, Blood 
creatine phosphokinase increased, Blood creatine phosphokinase MB, abnormal, Blood creatine 
phosphokinase MB increased, Cardiac enzymes increased, Cardiac stress test abnormal, Computerized 
tomogram coronary artery abnormal, Coronary artery aneurysm, Coronary angioplasty, Coronary 
arterial stent insertion, Coronary artery bypass, Coronary artery disease, Coronary artery dissection, 
Coronary artery embolism, Coronary artery insufficiency, Coronary artery occlusion, Coronary artery 
reocclusion, Coronary artery restenosis, Coronary artery stenosis, Coronary artery thrombosis, Coronary 
bypass thrombosis, Coronary endarterectomy, Coronary no-reflow phenomenon, Coronary ostial 
stenosis, Coronary revascularization, Dissecting coronary artery aneurysm, ECG electrically inactive area, 
ECG signs of myocardial ischemia, Electrocardiogram ST segment abnormal, Electrocardiogram ST 
segment depression, Electrocardiogram ST segment elevation, Electrocardiogram ST-T segment 
abnormal, Electrocardiogram ST-T segment depression, Electrocardiogram ST-T segment elevation, 
Electrocardiogram T wave abnormal, Electrocardiogram T wave inversion, Exercise electrocardiogram 
abnormal, Exercise test abnormal, External counterpulsation, Hemorrhage coronary artery, Infarction, 
Ischemic cardiomyopathy, Kounis syndrome, Microvascular coronary artery disease, Multiple gated 
acquisition scan abnormal, Myocardial infarction, Myocardial ischemia, Myocardial reperfusion injury, 
Myocardial stunning, Papillary muscle infarction, Percutaneous coronary intervention, Postprocedural 
myocardial infarction, Postinfarction angina, Prinzmetal angina, Silent myocardial infarction, Stress 
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cardiomyopathy, Stress echocardiogram abnormal, Subclavian coronary steal syndrome, Subendocardial 
ischemia, Troponin I increased, Troponin increased, Troponin T increased, Vascular graft occlusion.  
Ischemic CNS vascular conditions (MedDRA SMQ v17.1): Amaurosis fugax, Basal ganglia infarction, 
Basal ganglia stroke, Basilar artery occlusion, Basilar artery stenosis, Basilar artery thrombosis, 
Brachiocephalic arteriosclerosis, Brachiocephalic artery occlusion, Brachiocephalic artery stenosis, Brain 
hypoxia, Brain stem embolism, Brain stem infarction, Brain stem ischaemia, Brain stem stroke, Brain 
stem thrombosis, Capsular warning syndrome, Carotid angioplasty, Carotid arterial embolus, Carotid 
arteriosclerosis, Carotid artery bypass, Carotid artery disease, Carotid artery insufficiency, Carotid artery 
occlusion, Carotid artery restenosis, Carotid artery stenosis, Carotid artery stent insertion, Carotid artery 
stent removal, Carotid artery thrombosis, Carotid endarterectomy, Carotid revascularisation, Cerebellar 
artery occlusion, Cerebellar artery thrombosis, Cerebellar embolism, Cerebellar infarction, Cerebellar 
ischaemia, Cerebral arteriosclerosis, Cerebral artery embolism, Cerebral artery occlusion, Cerebral artery 
restenosis, Cerebral artery stenosis, Cerebral artery thrombosis, Cerebral gas embolism, Cerebral 
infarction, Cerebral infarction foetal, Cerebral ischaemia, Cerebral revascularisation, Cerebral septic 
infarct, Cerebral small vessel ischaemic disease, Cerebral thrombosis, Cerebral vasoconstriction, 
Cerebral venous thrombosis, Cerebrovascular accident, Cerebrovascular disorder, Cerebrovascular 
insufficiency, Cerebrovascular stenosis, Embolic cerebral infarction, Embolic hypoxic-ischaemic 
encephalopathy, Embolic stroke, Hypoxic-ischaemic encephalopathy, In-stent cerebral artery stenosis, 
Inner ear infarction, Ischaemic cerebral infarction, Ischaemic stroke, lacunar infarction, Lateral 
medullary syndrome, Migrainous infarction, Millard-Gubler syndrome, Moyamoya disease, Perinatal 
stroke , Post procedural stroke, Precerebral artery occlusion, Retinal artery occlusion, Reversible 
ischaemic neurological deficit, Spinal artery embolism, Spinal artery thrombosis, Stroke in evolution, 
Subclavian steal syndrome, Thalamic infarction, Thrombotic cerebral infarction, Thrombotic stroke, 
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Transient ischaemic attack, Vascular encephalopathy, Vertebral artery occlusion, Vertebral artery 
stenosis, Vertebral artery thrombosis, Vertebrobasilar insufficiency.  
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Supplementary Information 3 
CATEGORY: Cardiac disorders 
Adverse Event: Atrial fibrillation 
Short Name: Atrial fibrillation 
MedDRA Code: 10003658 
Grade Description 
1 Asymptomatic, intervention not indicated 
2 Non-urgent medical intervention indicated 
3 Symptomatic and incompletely controlled medically, or controlled with device (e.g. pacemaker), or ablation 
4 Life-threatening consequences; urgent intervention indicated 
5 Death 
 
  
 14 
 
Supplementary Information 4 
Ibrutinib dose modification for adverse events 
Interrupt ibrutinib therapy for any grade 3 or greater non-hematological adverse event, grade 3 or 
greater neutropenia with infection or fever or grade 4 hematological toxicities. Once the symptoms of 
the event have resolved to grade 1 or baseline (recovery), ibrutinib therapy may be reinitiated at the 
starting dose. If the event reoccurs, reduce dose by one capsule (140 mg per day). A second reduction of 
dose by 140 mg may be considered as needed. If these adverse events persist or recur following two 
dose reductions, discontinue ibrutinib. Recommended dose modifications are described below7: 
Toxicity occurrence 
CLL/SLL dose modification  
after recovery 
Starting dose = 420 mg 
MCL dose modification  
after recovery 
Starting dose = 560 mg 
First Restart at 420 mg daily Restart at 560 mg daily 
Second Restart at 280 mg daily Restart at 420 mg daily 
Third Restart at 140 mg daily Restart at 280 mg daily 
Fourth Discontinue ibrutinib Discontinue ibrutinib 
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Supplementary Table S1. Median duration of therapy by study (safety population). 
Study Median duration of therapy 
PCYC-1112 
(RESONATE, NCT01578707) 
Ibrutinib (N=195) 8.6 months (range: 0.2-16.1 months) 
Ofatumumab (N=191) 5.3 months (range: 0.0-7.4 months) 
PCYC-1115 
(RESONATE-2, NCT01722487) 
Ibrutinib (N=135) 17.4 months (range: 0.7-24.7 months) 
Chlorambucil (N=132) 7.1 months (range: 0.5-11.7 months) 
CLL3001 
(HELIOS, NCT01611090) 
Ibrutinib + BR (N=287) 14.7 months (range: 0.2-27.1 months) 
Placebo + BR (N=287) 12.8 months (range: 0.2-27.3 months) 
MCL3001 
(RAY, NCT01646021) 
Ibrutinib (N=139) 14.4 months (range: 0.0-28.2 months) 
Temsirolimus (N=139) 3.0 months (range: 0.0-27.0 months) 
Total 
Ibrutinib (N=756) 13.3 months (range: 0.0, 28.2 months) 
Comparator (N=749) 5.8 months (range: 0.0, 27.4) 
BR, bendamustine and rituximab. 
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Supplementary Table S2. Patients experiencing 1 or more AF episodes. 
AF, atrial fibrillation. 
 
  
Number of AF episodes 
Ibrutinib 
(n=49) 
Comparator 
(n=12) 
1  27 (55.1) 10 (83.3) 
2  16 (32.7) 2 (16.7) 
3  3 (6.1) 0 
4  3 (6.1) 0 
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Supplementary Table S3. Patients with multiple AF events. 
 
Ibrutinib 
(n=22) 
Comparator 
(n=2) 
Clinical characteristics   
Median age, years (range) 72.0 (59-84) 64.5 8 (58-71) 
<65, n (%) 2 (9.1) 1 (50.0) 
Male, n (%) 16 (72.7) 2 (100) 
Race (White), n (%) 21 (95.5) 2 (100) 
BMI, n (%)a   
>18-24.9 8 (36.4) 0 
25-29.9 11 (50.0) 1 (50.0) 
≥30 2 (9.1) 1 (50.0) 
Prior history for patients, n (%)   
AF/abnormal heart rhythm 7 (31.8) 2 (100) 
Comorbid cardiac condition 8 (36.4) 2 (100) 
Diabetes 3 (13.6) 0 
Hyperlipidemia 4 (18.2) 0 
Hypertension 14 (63.6) 2 (100) 
Infection 10 (45.5) 1 (50.0) 
Study drug management after AF   
No dose modification 7 (31.8) 1 (50.0) 
Drug interrupted 10 (45.5) 1 (50.0) 
Discontinued 5 (22.7) 0 
 Concomitant medications after AF 
Antiplatelets   
Aspirin 14 (63.6) 0 
Antiplatelets other than aspirin 4 (18.2) 0 
Anticoagulants   
Low-molecular-weight heparin 12 (54.5) 1 (50.0) 
Novel oral anticoagulants 4 (18.2) 1 (50.0) 
Vitamin K antagonists 3 (13.6) 0 
Other 1 (4.5) 0 
AF, atrial fibrillation; BMI, body mass index. 
aOne ibrutinib patient was missing BMI at baseline. 
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Supplementary Table S4. Incidence and characterization of AF events in patients on ibrutinib with 
extended follow-up. 
 
Patients with AF  
(n=78) 
Time to onset of initial event (months)  
Median (range) 5.7 (0.3-40.2) 
Mean (SD) 11.5 (11.10) 
Number of AF episodes   
1 49 (62.8) 
>1 29 (37.2) 
2 20 (25.6) 
3 5 (6.4) 
4 2 (2.6) 
6 2 (2.6) 
Treatment-emergent AF  
Grade 1/2 43 (55.1) 
SAEs 38 (48.7) 
Action taken with ibrutinib  
Dose reduction 5 (6.4) 
Dose interruption 25 (32.1) 
Treatment discontinuation 7 (9.0) 
AF, atrial fibrillation; SAEs, serious adverse events. 
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Supplementary Table S5. Baseline demographic and clinical characteristics of patients with AF events 
without and with treatment interruption 
 
Ibrutinib 
(n=756) 
Comparator 
(n=749) 
 
Patients with AF 
events without 
treatment 
interruption 
(n=25) 
Patients with 
AF events with 
treatment 
interruption 
(n=24) 
Patients with 
AF events 
without 
treatment 
interruption 
(n=8) 
Patients with 
AF events with 
treatment 
interruption 
(n=4) 
Median age, years (range) 69.0 (59-78) 73.0 (62-84) 70.0 (58-80) 72.5 (67-88) 
<65, n (%) 
≥65, n (%) 
7 (0.9) 
18 (2.4) 
2 (0.3) 
14 (1.9) 
1 (0.1) 
7 (0.9) 
0 
4 (0.5) 
Male, n (%) 18 (2.4) 15 (2.0) 5 (0.7) 4 (0.5) 
Race (White), n (%) 24 (3.2) 23 (3.0) 8 (1.1) 4 (0.5) 
BMI, n (%)a     
>18-24.9 9 (1.2) 8 (1.1) 1 (0.1) 1 (0.1) 
25-29.9 10 (1.3) 11 (1.5) 1 (0.1) 2 (0.3) 
≥30 6 (0.8) 3 (0.4) 6 (0.8) 1 (0.1) 
Initial diagnosis, n (%) 
CLL/SLL 
MCL 
21 (2.8) 
4 (0.5) 
 
22 (2.9) 
2 (0.3) 
5 (0.7) 
3 (0.4) 
 
4 (0.5) 
0 
Anticoagulant at baseline, n (%) 2 (0.3) 2 (0.3) 0 2 (0.3) 
Antiplatelet at baseline, n (%) 7 (0.9) 10 (1.3) 2 (0.3) 0  
Prior history for patients, n (%)     
AF/abnormal heart rhythm 7 (0.9) 6 (0.8) 1 (0.1) 2 (0.3) 
Coronary artery disease 1 (0.1) 2 (0.3) 0 0 
Diabetes 5 (0.7) 2 (0.3) 4 (0.5) 1 (0.1) 
Hyperlipidemia 9 (1.2) 7 (0.9) 2 (0.3) 0  
Hypertension 14 (1.9) 17 (2.2) 7 (0.9) 3 (0.4) 
Infection 17 (2.2) 9 (1.2) 3 (0.4) 2 (0.3) 
AF, atrial fibrillation; BMI, body mass index; CLL, chronic lymphocytic leukemia; MCL, mantle cell 
lymphoma; SLL; small lymphocytic lymphoma. 
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aTwo patients with ibrutinib had missing BMI at baseline.  
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Supplementary Table S6A. Concomitant use of ibrutinib with other medications in patients, during AF 
event. 
 
Ibrutinib 
(n=49) 
Comparator 
(n=12) 
Management during 
AF event 
Management during 
AF event 
n (%) 
Median 
duration 
(range), weeks n (%) 
Median duration (range), 
weeks 
Beta blockers or  
alpha blockers 
40 (81.6) 4.4 (0.1-20.6) 8 (66.7) 4.4 (0.4-10.0) 
Diuretics 18 (36.7) 4.4 (0.1-22.6) 8 (66.7) 2.4 (0.1-5.4) 
ACE inhibitors 19 (38.8) 4.6 (3.4-18.0) 4 (33.3) 3.1 (0.1-4.4) 
Calcium channel 
blockers 
12 (24.5) 4.4 (0.1-15.3) 3 (25.0) 0.3 (0.1-4.4) 
Antiarrhythmic  18 (36.7) 3.9 (0.1-18.0) 7 (58.3) 3.9 (0.1-8.6) 
Digoxin 11 (22.4) 1.6 (0.1-9.9) 1 (8.3) 0.1 (0.1-0.1) 
Lipid-lowering 
medications, statins, 
and antidiabetics 
21 (42.9) 4.7 (0.1-19.6) 4 (33.3) 3.0 (0.6-4.7) 
Antiplatelets 
Aspirin 23 (46.9) 4.4 (0.1-15.9) 3 (25.0) 2.0 (2.0-4.3) 
Antiplatelets 
other than aspirin 
8 (16.3) 4.2 (0.6-9.9) 0 0 
Anticoagulants 
Low-molecular-
weight heparin 
20 (40.8) 3.3 (0.1-15.3) 7 (58.3) 2.0 (0.9-4.4) 
Novel oral 
anticoagulants 
10 (20.4) 4.4 (2.0-9.9) 1 (8.3) 9.1 (9.1-9.1) 
Vitamin K 
antagonists  
5 (10.2) 4.0 (0.3-4.4) 2 (16.7) 3.3 (2.1-4.4) 
Other 4 (8.2) 0.6 (0.1-4.4) 1 (8.3) 4.4 (4.4-4.4) 
ACE, angiotensin-converting-enzyme; AF, atrial fibrillation. 
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Supplementary Table S6B. Use of other medications during the course of study participation, in 
patients who experienced AF. 
 
Ibrutinib 
(n=49) 
Comparator 
(n=12) 
n (%) 
Median duration 
while on study 
(range), weeks n (%) 
Median duration 
while on study 
(range), weeks 
Beta blockers or  
alpha blockers 
41 (83.7) 54.4 (0.1-194.4) 9 (75.0) 57.9 (0.4-114.4) 
Diuretics 23 (46.9) 39.9 (0.1-148.6) 8 (66.7) 3.1 (0.3-21.6) 
ACE inhibitors 19 (38.8) 56.7 (4.6-143.0) 5 (41.7) 6.3 (0.6-104.0) 
Calcium channel 
blockers 
16 (32.7) 28.7 (0.1-80.3) 3 (25.0) 6.0 (0.1-10.4) 
Antiarrhythmic  25 (51.0) 9.1 (0.1-66.1) 7 (58.3) 20.9 (0.1-77.1) 
Digoxin 13 (26.5) 1.3 (0.1-19.7) 1 (8.3) 0.1 (0.1-0.1) 
Lipid-lowering 
medications, statins, 
and antidiabetics  
22 (44.9) 59.5 (0.1-114.3) 5 (41.7) 10.0 (4.1-152.1) 
Antiplatelets 
Aspirin 23 (46.9) 50.3 (2.1-103.9) 4 (33.3) 4.4 (2.0-61.0) 
Antiplatelets other 
than aspirin 
10 (20.4) 18.1 (0.1-74.9) 0 0 
Anticoagulants 
Low-molecular-
weight heparin 
25 (51.0) 4.3 (0.1-50.4) 7 (58.3) 2.4 (0.9-45.1) 
Novel oral 
anticoagulants 
12 (24.5) 40.9 (2.3-99.1) 1 (8.3) 87.3 (87.3-87.3) 
Vitamin K antagonists 7 (14.3) 13.0 (0.3-55.0) 2 (16.7) 4.1 (2.1-6.0) 
Other 8 (16.3) 0.4 (0.1-76.1) 1 (8.3) 67.6 (67.6-67.6) 
ACE, angiotensin-converting-enzyme; AF, atrial fibrillation. 
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Supplementary Table S7. CHA2DS2-VASc scores for patients in the pooled analysis. 
CHA2DS2-VASc score 
Ibrutinib 
(N=756) 
Comparator 
(N=749) 
Patients with AF  
(n=49)  
Patients without 
AF 
(n=707) 
Patients with AF 
(n=12) 
Patients without 
AF 
(n=737) 
0  6.1% 15.1% 0 16.0% 
1 22.4% 27.2% 16.7% 28.5% 
2 20.4% 27.7% 25.0% 23.3% 
3 32.7% 17.4% 16.7% 19.3% 
4 12.2% 10.5% 41.7% 9.2% 
5 4.1% 2.0% 0 3.1% 
6 2.0% 0.1% 0 0.5% 
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Supplementary Table S8. Brief narrative of patients randomized to ibrutinib with bleeding events 
leading to death. 
Patient 1, ruptured 
abdominal aortic 
aneurism 
A 75-year-old white man with CLL entered the study with an ongoing history 
of arterial hypertension, hyperlipidemia, and an abdominal aortic aneurysm. 
At study entry, the aneurysm was 7.8 cm in diameter. On study day 40 it 
ruptured and the subject died during an endovascular procedure to repair the 
aneurysm. 
Patient 2, post-
procedural hemorrhage 
A 72-year-old white man with CLL who had an SAE of hematochezia on study 
day 128. Ibrutinib was held and then restarted at a reduced dose of 280 
mg/day on study day 140. On study day 170 a colonoscopy to remove a grade 
3 villous adenoma (which was a cause of hematochezia) was performed; drug 
was not held as per the protocol guidance; grade 5 post-procedural 
hemorrhage occurred concurrently with a grade 5 event of colon perforation 
on study day 170 at the location of an abdominal drain site. 
Patient 3, subdural 
hematoma 
A 74-year-old white man with MCL with a grade 1 AE of head injury (date not 
specified); no action was taken with the study drug and no treatment was 
reported. On study day 501, a grade 4 SAE of subdural hematoma and a non-
serious AE of grade 1 confusional state were reported. Treatment with the 
study drug was discontinued on study day 501 due to the event of subdural 
hematoma, with the last dose received on the same day. On study day 523, 
the subject died due to subdural hematoma. 
AE, adverse event; CLL, chronic lymphocytic leukemia; MCL, mantle cell lymphoma; SAE, serious adverse 
event. 
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Supplementary Table S9. Clinical sequelae for patients with AF. 
Patients with AF 
Ibrutinib 
(n=49) 
Comparator 
(n=12) 
Single AF event 27 (55.1) 10 (83.3) 
Sequelaea 
Medical historyb 
No medical history 
5 (10.2) 
3 (6.1) 
2 (4.1) 
2 (16.7) 
2 (16.7) 
0 
No sequelae 
Medical historyb 
No medical history 
22 (44.9) 
16 (32.7) 
6 (12.2) 
8 (66.7) 
6 (50.0) 
2 (16.7) 
Multiple AF events 22 (44.9) 2 (16.7) 
Sequelaea 
Medical historyb 
No medical history 
13 (26.5) 
9 (18.4) 
4 (8.2) 
2 (16.7) 
2 (16.7) 
0 
No sequelae 
Medical historyb 
No medical history 
9 (18.4) 
7 (14.3) 
2 (4.1) 
0 
AF, atrial fibrillation. 
aSequelae include chronic heart failure, ischemic cardiac events, arrhythmias and/or hypertension. 
bMedical history includes history of chronic heart failure, ischemic cardiac events, arrhythmias and/or 
hypertension. 
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